Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: A retrospective cohort study - 16/07/22
Doi : 10.1016/j.jaad.2021.06.885
Ai-Tram N. Bui, MD a, b, Amina Bougrine, MD b, Elizabeth I. Buchbinder, MD c, Anita Giobbie-Hurder, MS d, Nicole R. LeBoeuf, MD, MPH a, c, e, ⁎ 
a Harvard Medical School, Boston, Massachusetts
b Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts
c Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts
d Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts
e Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts
∗Correspondence and reprint requests to: Nicole R. LeBoeuf, MD, MPH, Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, 450 Brookline Avenue, Boston, MA 02115Center for Cutaneous OncologyDana-Farber/Brigham and Women's Cancer Center450 Brookline AvenueBostonMA02115
| Funding sources: None. |
|
| IRB approval status: Approved by the Partners Healthcare Institutional Review Board (#2015P001336). |
© 2021
Publié par Elsevier Masson SAS.
Vol 87 - N° 2
P. 403-406 - août 2022 Retour au numéro
Article précédent
- Topical Janus kinase-signal transducers and activators of transcription inhibitor tofacitinib is effective in reducing nonatopic dermatitis chronic itch: A case series
- Teresa Ju, Angelina Labib, Ashley Vander Does, Gil Yosipovitch
- No increased incidence of Clostridium difficile infection among patients with hidradenitis suppurativa treated with systemic clindamycin
- Ruby Kwak, Christina G. Lopez, Megan H. Noe, Vinod E. Nambudiri, Alexandra P. Charrow
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?